A Study in Migraine Prevention

Summary

The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.

Timeline

Start

2011-01

Primary completion

2012-04

Completion

2012-04

Outcome

Missed primary endpoint

Stopped: “Elevation of ALT and AST in some patients.”

registry Placebo vs LY2300559; p = 0.085; Least squares (LS) mean difference (Net) -1.03 (90% CI -2.02 to -0.05) NCT01184508 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2300559	Small molecule	300 mg	Oral

Indications